Skip to main content

Advertisement

SpringerLink
Log in

Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

There is no data availability statement as this is a case report.

References

  1. Kleinschmidt-DeMasters BK (2005) Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. N Engl J Med 353:369

    Article  CAS  PubMed  Google Scholar 

  2. Brinkmann V, Davis MD, Heise CE et al (2002) The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors. J Biol Chem 277:21453–21457. https://doi.org/10.1074/jbc.C200176200

    Article  CAS  PubMed  Google Scholar 

  3. Berger JR, Cree BA, Greenberg B et al (2018) Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90:e1815–e1821. https://doi.org/10.1212/WNL.0000000000005529

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sriwastava S, Chaudhary D, Srivastava S et al (2022) Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. J Neurol 269:1678–1687. https://doi.org/10.1007/s00415-021-10910-1

    Article  CAS  PubMed  Google Scholar 

  5. Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med 380:1597–1605. https://doi.org/10.1056/NEJMoa1815039

    Article  CAS  PubMed  Google Scholar 

  6. Roos-Weil D, Weiss N, Guihot A et al (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? J Neurol 268:2458–2465. https://doi.org/10.1007/s00415-021-10414-y

    Article  CAS  PubMed  Google Scholar 

  7. Boumaza X, Bonneau B, Roos-Weil D et al (2022) Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors. Ann Neurol. https://doi.org/10.1002/ana.26512

    Article  PubMed  PubMed Central  Google Scholar 

  8. Major EO, Yousry TA, Clifford DB (2018) Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 17:467–480. https://doi.org/10.1016/S1474-4422(18)30040-1

    Article  CAS  PubMed  Google Scholar 

  9. Barber DL, Wherry EJ, Masopust D et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682–687. https://doi.org/10.1038/nature04444

    Article  CAS  PubMed  Google Scholar 

  10. Tan CS, Bord E, Broge TA et al (2012) Increased Program Cell Death–1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy. JAIDS J Acquir Immune Defic Syndr 60:244–248. https://doi.org/10.1097/QAI.0b013e31825a313c

    Article  CAS  PubMed  Google Scholar 

  11. Lombardo-del Toro P, Bragado-Trigo I, Arroyo P et al (2023) Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim. J Neurol. https://doi.org/10.1007/s00415-023-11865-1

    Article  PubMed  Google Scholar 

  12. Redelman-Sidi G, Michielin O, Cervera C et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 24:S95–S107. https://doi.org/10.1016/j.cmi.2018.01.030

    Article  PubMed  PubMed Central  Google Scholar 

  13. Tyler KL, Vollmer TL (2017) To PLEX or not to PLEX in natalizumab-associated PML. Neurology 88:1108–1109. https://doi.org/10.1212/WNL.0000000000003747

    Article  PubMed  Google Scholar 

  14. Landi D, De Rossi N, Zagaglia S et al (2017) No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88:1144–1152. https://doi.org/10.1212/WNL.0000000000003740

    Article  CAS  PubMed  Google Scholar 

  15. Mickeviciene D, Baltusiene A, Afanasjeva B et al (2022) Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A Case Report. BMC Neurol 22:306. https://doi.org/10.1186/s12883-022-02839-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study did not receive any funding.

Author information

Authors and Affiliations

  1. Département de neurologie, unité de Médecine Intensive Réanimation à orientation neurologique, Sorbonne Université, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France

    Lina Jeantin & Nicolas Weiss

  2. Department of Neuroradiology, Sorbonne Université, AP-HP, Hôpital de la Pitié-Salpêtrière, 47-83 Bd de l’Hôpital, Paris, France

    Natalia Shor

  3. Department of Neurology, Orléans Hospital, 14 avenue de l’Hôpital, Orléans, France

    Maud Pallix-Guyot

  4. Department of Clinical Hematology, Pitié–Salpétrière University Hospital, 47-83 Bd de l’Hôpital, Paris, France

    Damien Roos-Weil

  5. Département de Santé Publique, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié Salpêtrière, Paris, France

    Agnès Bellanger

  6. Department of Biological Hematology, Sorbonne Université, AP-HP, Hôpital de la Pitié-Salpêtrière, 47-83 Bd de l’Hôpital, 75013, Paris, France

    Magali Le Garff-Tavernier

  7. Department of Neurology, Hospital Foundation Adolphe de Rothschild, 25-29 rue Manin, Paris, France

    Caroline Papeix

  8. Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France & Groupe de Recherche Clinique en REanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE) Sorbonne Université, Paris, France

    Nicolas Weiss

  9. Service des Maladies infectieuses et tropicales, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié Salpêtrière, Paris, France

    Valérie Pourcher

Authors
  1. Lina Jeantin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalia Shor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maud Pallix-Guyot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Damien Roos-Weil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Agnès Bellanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Magali Le Garff-Tavernier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caroline Papeix
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nicolas Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Valérie Pourcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LJ wrote the first draft of the manuscript. NS designed the figure. All authors participated in the diagnosis and therapy deliberation. All authors reviewed and approved the final manuscript.

Corresponding author

Correspondence to Valérie Pourcher.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jeantin, L., Shor, N., Pallix-Guyot, M. et al. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod. J Neurol 271, 729–732 (2024). https://doi.org/10.1007/s00415-023-12055-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-12055-9

Search

Navigation